top of page

EC MDCG Guidance on Legacy Medical Devices, Repackaging Data

Writer's picture: Sharan MuruganSharan Murugan

The European Commission’s Medical Device Coordination Group (MDCG) released a document detailing how the newly implemented Medical Device Regulation (MDR) will be applied to legacy devices.

Legacy devices should be understood as devices, which, in accordance with Article 120(3) of the MDR, are placed on the market after the MDR’s date of application (DoA) and until 26 May 2024 if certain conditions are fulfilled. Those devices can be:

  • devices which are class I devices under Directive 93/42/EEC (MDD), for which an EC declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure under the MDR requires the involvement of a notified body;

  • devices covered by a valid EC certificate issued in accordance with Directive 90/385/EEC (AIMDD) or the MDD prior to 26 May 2021. ‘Old’ devices are those devices that were placed on the market before 26 May 2021 in accordance with the AIMDD or the MDD or in accordance with the applicable rules before the Directives had entered into force.

MDR devices are those that are placed on the market as being in conformity with the MDR other than ‘legacy devices’.


With this document, the task-force reports back to the MDCG about its position on the applicability of MDR requirements to ‘legacy devices’ and ‘old’ devices


In a separate Q&A document, MDCG outlined regulatory obligations for medical devices and in vitro diagnostic (IVD) medical devices related to repackaging and relabeling.

Comentarios


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page